indication-specific pricing

Market Access

Leela Barham highlights data that shows that indication-specific pricing has been used in England for at least four years and over 60 times.

News

Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.